RT Journal Article
SR Electronic
T1 Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.27.20082289
DO 10.1101/2020.04.27.20082289
A1 Garcia-Basteiro, Alberto L
A1 Moncunill, Gemma
A1 Tortajada, Marta
A1 Vidal, Marta
A1 Guinovart, Caterina
A1 Jiménez, Alfons
A1 Santano, Rebeca
A1 Sanz, Sergi
A1 Méndez, Susana
A1 Llupià, Anna
A1 Aguilar, Ruth
A1 Alonso, Selena
A1 Barrios, Diana
A1 Carolis, Carlo
A1 Cisteró, Pau
A1 Chóliz, Eugenia
A1 Cruz, Angeline
A1 Folchs, Silvia
A1 Jairoce, Chenjerai
A1 Hecht, Jochen
A1 Lamoglia, Montserrat
A1 Martínez, Mikel J.
A1 Mitchell, Robert A.
A1 Ortega, Natalia
A1 Pey, Nuria
A1 Puyol, Laura
A1 Ribes, Marta
A1 Rosell, Neus
A1 Sotomayor, Patricia
A1 Torres, Sara
A1 Williams, Sarah
A1 Barroso, Sonia
A1 Vilella, Anna
A1 Muñoz, José
A1 Trilla, Antoni
A1 Varela, Pilar
A1 Mayor, Alfredo
A1 Dobaño, Carlota
YR 2020
UL http://medrxiv.org/content/early/2020/05/02/2020.04.27.20082289.abstract
AB Background Health care workers (HCW) are a high-risk population to acquire SARS-CoV-2 infection from patients or other fellow HCW. At the same time, they can be contagious to highly vulnerable individuals seeking health care. This study aims at estimating the seroprevalence of antibodies against SARS-CoV-2 and associated factors in HCW from a large referral hospital in Barcelona, Spain, one of the countries hardest hit by COVID-19 in the world.Methods From 28 March to 9 April 2020, we recruited a random sample of 578 HCW from the human resources database of Hospital Clínic in Barcelona. We collected a nasopharyngeal swab for direct SARS-CoV-2 detection through real time reverse-transcriptase polymerase chain reaction (rRT-PCR), as well as blood for plasma antibody quantification. IgM, IgG and IgA antibodies to the receptor-binding domain of the spike protein were measured by Luminex. The cumulative prevalence of infection (past or current) was defined by a positive SARS-CoV-2 rRT-PCR and/or antibody seropositivity.Results Of the 578 total participants, 39 (6.7%, 95% CI: 4.8-9.1) had been previously diagnosed with COVID-19 by rRT-PCR, 14 (2.4%, 95% CI: 1.4-4.3) had a positive rRT-PCR at recruitment, and 54 (9.3%, 95% CI: 7.2-12.0) were seropositive for IgM and/or IgG and/or IgA against SARS-CoV-2. Of the 54 seropositive HCW, 21 (38.9%) had not been previously diagnosed with COVID-19, although 10 of them (47.6%) reported past COVID-19-compatible symptoms. The cumulative prevalence of SARS-CoV-2 infection was 11.2% (65/578, 95% CI: 8.9-14.1). Among those with evidence of past or current infection, 40.0% (26/65) had not been previously diagnosed with COVID-19, of which 46.2% (12/26) had history of COVID-19-compatible symptoms. The odds of being seropositive was higher in participants who reported any COVID-19 symptom (OR: 8.84, 95% CI: 4.41-17.73). IgM levels positively correlated with age (rho=0.36, p-value=0.031) and were higher in participants with more than 10 days since onset of symptoms (p-value=0.022), and IgA levels were higher in symptomatic than asymptomatic subjects (p-value=0.041).Conclusions The seroprevalence of antibodies against SARS-CoV-2 among HCW was lower than expected. Thus, being a high-risk population, we anticipate these estimates to be an upper limit to the seroprevalence of the general population. Forty per cent of those with past or present infection had not been previously diagnosed with COVID-19, which calls for active periodic rRT-PCR testing among all HCW to minimize potential risk of hospital-acquired SARS-CoV-2 infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding from this study comes from internal ISGlobal funds and in-kind contributions from Hospital Clínic and CRG.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual patient data is not available yet.